Spitalul Clinic Coltea
- Address
- lock Available on a paid plan
Spitalul Clinic Coltea - Hematology & Oncology Research Center
Spitalul Clinic Coltea is a distinguished clinical research institution specializing in hematologic malignancies and advanced oncology therapeutics. The center demonstrates particular expertise in conducting complex Phase 3 trials evaluating novel targeted therapies and combination treatment regimens for blood cancers and solid tumors.
- Lymphoma research including follicular, marginal zone, chronic lymphocytic leukemia, and non-Hodgkin lymphoma with focus on BTK inhibitors and immunomodulatory combinations
- Acute myeloid leukemia trials investigating mutation-specific targeted therapies, particularly IDH1-mutation positive disease
- Advanced lung cancer studies focusing on MET-amplified non-small cell lung cancer and antibody-drug conjugate therapeutics
- Immunoglobulin replacement therapy for hypogammaglobulinemia and infection prevention in hematologic malignancies
The research center's portfolio reflects expertise in evaluating precision medicine approaches, including biomarker-driven patient selection and molecularly targeted agents. The facility actively participates in international multi-center trials comparing emerging therapeutic combinations against standard-of-care regimens, with particular emphasis on improving outcomes for patients with relapsed/refractory hematologic conditions and metastatic solid tumors ineligible for intensive treatment approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 104 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 102 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
- 1BioNTech SE2active
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG4trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Clinic Coltea
lock Showing 1 of 46 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009) | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Jul 2020 | Sep 2025 |
IMP list
lock Showing 1 of 104 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 7 | Unknown | 2020-07-16 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.